About 718 results

ALLMedicine™ Anaplastic Thyroid Carcinoma Center

Research & Reviews  272 results

Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeu...
https://doi.org/10.1007/978-3-030-83282-7_2 10.1016/S0092-8674(00)81683-9 10.1016/j.cell.2011.02.013 10.1111/j.1600-065X.1971.tb00461.x 10.1111/j.1600-065X.1976.tb00189.x 10.1038/nm.3909 10.1038/nri3920 10.1038/ni.3341 10.3389/fimmu.2015.00486 10.1158/0008-5472.CAN-07-0912 10.1016/j.ccr.2011.02.005 10.1016/j.ccell.2017.07.001 10.1038/s41577-019-0127-6 10.1016/j.cell.2008.09.016 10.20900/immunometab20190015 10.3390/cancers11060750 10.3389/fonc.2019.01143 10.1242/dmm.034272 10.1007/s00262-018-2195-z 10.3389/fimmu.2019.00925 10.1158/1078-0432.CCR-14-0291 10.1126/science.1198687 10.1038/sj.emboj.7600019 10.1016/j.intimp.2018.09.016 10.1038/nri3442 10.3892/ol.2017.5681 10.3389/fcell.2020.00766 10.3389/fimmu.2019.00147 10.1101/cshperspect.a006536 10.3390/ijms19051272 10.1186/s12943-017-0597-8 10.1016/j.semcancer.2019.06.003 10.1038/nrc.2016.73 10.1186/s12967-018-1536-1 10.3390/ijms19051532 10.3389/fimmu.2019.01835 10.1097/PPO.0000000000000118 10.1098/rsob.190297 10.3389/fonc.2020.00569 10.3389/fonc.2020.00722 10.1016/j.canlet.2019.07.010 10.1016/j.semcancer.2014.02.007 10.1038/s41423-020-0505-9 10.1016/j.immuni.2019.06.025 10.3390/ijms21155521 10.1016/j.cell.2004.07.011 10.1016/j.ccr.2013.03.004 10.1172/JCI39104 10.1038/nrm1835 10.1084/jem.20051848 10.1016/j.ccr.2012.04.024 10.1158/2326-6066.CIR-15-0241 10.1242/jcs.237453 10.1093/carcin/bgu060 10.3803/EnM.2013.28.3.192 10.1677/ERC-08-0036 10.1371/journal.pone.0022567 10.1002/path.1731 10.3892/mco.2013.170 10.1111/cen.12586 10.3892/ol.2019.9940 10.1073/pnas.0509182102 10.1097/MD.0000000000006472 10.3389/fonc.2019.01270 10.1038/s41416-019-0540-4 10.1158/10780432 10.1530/ERC-16-0421 10.1126/science.aar4060 10.1038/nrm3758 10.1007/s10911-010-9178-9 10.1074/jbc.M113.528026 10.1371/journal.pone.0036132 10.1038/srep09489 10.1016/j.stemcr.2014.03.008 10.1038/sj.bjc.6605530 10.1016/j.cell.2004.06.006 10.1016/j.tcb.2015.07.012 10.1101/gad.225334.113 10.1242/jcs.02552 10.1074/jbc.M005912200 10.1016/j.ccr.2009.03.016 10.1038/sj.onc.1210546 10.1016/j.canlet.2013.02.033 10.1186/s12902-019-0351-x 10.1158/0008-5472.CAN-05-2514 10.4049/JIMMUNOL.172.7.4100 10.1158/1078-0432.CCR-11-1595 10.1155/2013/857519 10.1186/s40425-018-0378-y 10.1097/CMR.0000000000000355 10.1210/jc.2018-01167 10.1016/j.immuni.2016.04.019 10.1016/j.prp.2019.04.002 10.3390/ijms20092198 10.1189/jlb.0809590 10.1172/JCI120966 10.1158/0008-5472.CAN-17-1653 10.1002/mc.22418 10.1158/1535-7163.MCT-19-0183
Advances in Experimental Medicine and Biology; Chakraborty S, Carnazza M et. al.

Dec 11th, 2021 - Thyroid cancer incidence is increasing at an alarming rate, almost tripling every decade. About 44,280 new cases of thyroid cancer (12,150 in men and 32,130 in women) are estimated to be diagnosed in 2021, with an estimated death toll of around 22...

Carcinoma Showing Thymus-like Differentiation (CASTLE) with Synchronous Papillary Thyro...
Ear, Nose, & Throat Journal; Hsu YC, Hsueh C et. al.

Dec 7th, 2021 - Carcinoma showing thymus-like differentiation (CASTLE) is a rare malignant tumor that accounts for 0.1%-0.15% of all thyroid cancers. More than half of the patients have tumor extension to adjacent organs, including the recurrent laryngeal nerve, ...

miR-381-3p attenuates doxorubicin resistance in human anaplastic thyroid carcinoma via ...
International Journal of Experimental Pathology; Zhang Y, Li K et. al.

Nov 2nd, 2021 - Abnormal microRNA (miR) expression has frequently been reported to be implicated in cancer-related drug resistance. Herein, we planned to investigate whether miR-381-3p contributes to doxorubicin (DOX) resistance in anaplastic thyroid carcinoma (A...

Thyroid crisis caused by metastatic thyroid cancer: an autopsy case report.
BMC Endocrine Disorders; Takedani K, Notsu M et. al.

Oct 26th, 2021 - Thyroid crisis is a life-threatening condition in thyrotoxic patients. Although differentiated thyroid cancer is one of the causes of hyperthyroidism, reports on thyroid crisis caused by thyroid cancer are quite limited. Here, we describe a case o...

see more →

Guidelines  3 results

The revised clinical practice guidelines on the management of thyroid tumors by the Jap...
Endocrine Journal; Ito Y, Onoda N et. al.

Apr 10th, 2020 - The Japan Associations of Endocrine Surgeons has developed the revised version of the Clinical Practice Guidelines for Thyroid Tumors. This article describes the guidelines translated into English for the 35 clinical questions relevant to the ther...

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.
Journal of the National Comprehensive Cancer Network : JN... Haddad RI, Nasr C et. al.

Dec 14th, 2018 - The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summa...

Anaplastic Thyroid Carcinoma, Version 2.2015.
Journal of the National Comprehensive Cancer Network : JN... Haddad RI, Lydiatt WM et. al.

Sep 12th, 2015 - This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosage...

see more →

Clinicaltrials.gov  2 results

Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients

Aug 3rd, 2017 - The objectives of this study are to evaluate safety, efficacy and pharmacokinetics of sorafenib for the treatment of Japanese patients with anaplastic thyroid carcinoma (ATC) or locally advanced or metastatic medullary thyroid carcinoma (MTC).

Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma

Apr 21st, 2014 - Anaplastic thyroid carcinomas (ATC) are high grade neoplasms, which account for approximately 2% to 5% of primary malignant thyroid tumors but more than 50% of thyroid cancer deaths. Because therapies for anaplastic thyroid carcinoma are very limi...

see more →

News  10 results

Next-Generation BRAF Inhibitor Plus Cobicistat Elicits Encouraging Activity in BRAF+ Refractory Solid Tumors

Oct 6th, 2021 - PLX8394, a next-generation BRAF inhibitor, in combination with cobicistat (Tybost) was found to demonstrate encouraging clinical activity with an acceptable safety profile in patients with BRAF-mutated, refractory solid tumors, according to result...

Advanced HCC: What's Next?

Apr 2nd, 2021 - Transcript: Ghassan K. Abou-Alfa, MD: I would like to end our very valuable discussion here by asking each one of you about—all right, great, out of nothing we moved in the speed of light. I’m not sure even if there is any other disease that w...

Targeted Treatment Tied to Longer Survival in Patients With Anaplastic Thyroid Cancer

Aug 21st, 2020 - NEW YORK (Reuters Health) - With the introduction of targeted treatments for anaplastic thyroid carcinoma, patients have seen significant improvements in survival, according to a new report. "Over the last 5 years, a greater understanding of the m...

Targeted Treatment Tied to Longer Survival in Patients With Anaplastic Thyroid Cancer

Aug 21st, 2020 - NEW YORK (Reuters Health) - With the introduction of targeted treatments for anaplastic thyroid carcinoma, patients have seen significant improvements in survival, according to a new report. "Over the last 5 years, a greater understanding of the m...

Lichenoid dermatitis with mycosis fungoides features linked to checkpoint inhibitor therapy
Bianca Nogrady

Jul 28th, 2019 - A patient treated with immune checkpoint inhibitor therapy for thyroid carcinoma presented with lichenoid dermatitis that resembled mycosis fungoides and also showed with monoclonal T-cell receptor gene rearrangement. A case report published in th.

see more →